LAM561 Emerging Drug Insight and Market Forecast - 2032

This “LAM561 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about LAM561 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the LAM561 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LAM561 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LAM561 market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

LAM561 (2-OHOA: 2-hydroxyoleic acid) is the first-in-class anticancer drug acting through cell membrane lipid modification. LP561A1 is an orally bioavailable synthetic derivative of oleic acid that crosses the blood-brain barrier and activates SMS1 expression with Ras signaling modulator effects. This key enzyme regulates phospholipid concentrations at the plasma membrane, particularly sphingolipid. Membrane lipid composition and organization are significantly altered in cancer cells. These changes have been observed to increase recruitment to the cell membrane of central proliferation signaling proteins, such as K-Ras. Aberrant activity of Ras-associated proliferative signaling pathways is found in at least one-third of all human cancers. It induces translocation of K-Ras from its active domain in the plasma membrane to the cytosolic membranes and inhibits its nanoclustering and signaling, inactivating key Ras-dependent proliferation pathways (like Ras/MAPK, Pi3K/AKT/mTOR or PKC/Cyclin CDK), causing endoplasmic reticulum stress, cell cycle arrest and eventually selective death of cancer cells.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the LAM561 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on LAM561 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LAM561 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around LAM561.
• The report contains forecasted sales of LAM561 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for LAM561 in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LAM561 Analytical Perspective

In-depth LAM561 Market Assessment

This report provides a detailed market assessment of LAM561 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

LAM561 Clinical Assessment

The report provides the clinical trials information of LAM561 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LAM561 dominance.
• Other emerging products for GBM are expected to give tough market competition to LAM561 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LAM561 in GBM.
• This in-depth analysis of the forecasted sales data of LAM561 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LAM561 in GBM.

Key Questions

• What is the product type, route of administration and mechanism of action of LAM561?
• What is the clinical trial status of the study related to LAM561 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LAM561 development?
• What are the key designations that have been granted to LAM561 for GBM?
• What is the forecasted market scenario of LAM561 for GBM?
• What are the forecasted sales of LAM561 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to LAM561 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

This product will be delivered within 2 business days.